ANTIBIOTIC THERAPY IN SEVERE SEPSIS IN HIV-POSITIVE PATIENTS

被引:0
|
作者
Dorobat, Carmen-Mihaela [1 ,3 ]
Dorobat, G. [2 ]
Bejan, Codrina [1 ,3 ]
Ghibu, Laura [1 ,3 ]
Rosu, F. [3 ]
Petrovici, Cristina [1 ,3 ]
Loghin, Isabela [3 ]
Manciuc, Carmen [1 ,3 ]
机构
[1] Univ Med & Pharm Grigore T Popa Iasi, Sch Med, Discipline Infect Dis, Iasi, Romania
[2] Univ Med & Pharm Grigore T Popa Iasi, Clin Hosp Neurosurgery Prof N Oblu Iasi, Sch Med, Iasi, Romania
[3] Univ Med & Pharm Grigore T Popa Iasi, Clin Hosp Infect Dis Sf Parascheva Iasi, Sch Med, Iasi, Romania
来源
MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA | 2012年 / 116卷 / 03期
关键词
HIV INFECTION; SEPSIS; ORGAN FALURE; ANTIBIOTIC THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Severe sepsis has become one of the most frequent causes of hospitalization in intensive care units for patients diagnosed with HIV infection. The difficulty in setting a sepsis diagnosis in HIV-positive patients led to the systematic exclusion of these patients from studies on sepsis, which limited the understanding of its impact on the evolution of the disease. Our study aims to evaluate the etiology of sepsis in immunocompromised HIV-positive patients and the evolution after antibiotic therapy. 30 patients diagnosed with HIV infection and sepsis, admitted to our clinic between January 2008 and April 2012, were followed. Severity of illness, time since diagnosis, CD4 count, antiretroviral treatment, incidence of severe sepsis, and organ dysfunctions were registered. Patients were between 1 and 61 years of age, most of them were classified into stages B2, B3 and C3, requiring hospitalization for a period ranging from 14 to 28 days, with an average of 16.7 days and a median of 18 days, while 8 required monitoring in the intensive care unit. In about 40% of cases, the starting point was an infection of the lower respiratory tract, but also of the upper urinary tract and skin infections. Evolution and mortality in sepsis associated with HIV/AIDS infection depend on the presence of organ failure and are less influenced by the level of immunodepression, complex antibiotic therapy being the cornerstone in controlling patients.
引用
收藏
页码:714 / 717
页数:4
相关论文
共 50 条
  • [1] Renal replacement therapy in HIV-positive patients
    Viertel, A
    Scherberich, JE
    Geiger, H
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1998, 27 (08) : 361 - 367
  • [2] Characteristics and risk factors for death in HIV-positive talaromycosis marneffei patients with sepsis
    Wang, Mengyan
    Dong, Xiaotian
    Wan, Hu
    Zhang, Binhai
    Yu, Lele
    Yu, Wenyan
    Zhang, Yan
    Pan, Kenv
    Wang, Miaochan
    Xu, Aifang
    Jin, Yujiao
    HELIYON, 2024, 10 (13)
  • [3] Atherosclerosis in HIV-positive patients
    Neumann, T
    Miller, M
    Esser, S
    Gerken, G
    Erbel, R
    ZEITSCHRIFT FUR KARDIOLOGIE, 2002, 91 (11): : 879 - +
  • [4] Pylephlebitis as a Complication of Cholangitis and Sepsis in an HIV-Positive Patient
    Zardi, Enrico Maria
    Giorgi, Chiara
    Zardi, Domenico Maria
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (06) : 1719 - 1721
  • [5] Pylephlebitis as a Complication of Cholangitis and Sepsis in an HIV-Positive Patient
    Enrico Maria Zardi
    Chiara Giorgi
    Domenico Maria Zardi
    Digestive Diseases and Sciences, 2019, 64 : 1719 - 1721
  • [6] Strategies for empiric antibiotic therapy in severe sepsis
    Duszynska, Wieslawa
    ANAESTHESIOLOGY INTENSIVE THERAPY, 2012, 44 (02) : 96 - 103
  • [7] Sublingual allergen immunotherapy in HIV-positive patients
    Iemoli, E.
    Borgonovo, L.
    Fusi, A.
    Magni, C.
    Ricci, E. D.
    Rizzardini, G.
    Piconi, S.
    ALLERGY, 2016, 71 (03) : 412 - 415
  • [8] Metabolic syndrome and hyperlipidemia in HIV-positive patients
    Behrens, GMN
    HERZ, 2005, 30 (06) : 458 - 466
  • [9] RISK-FACTORS FOR SEVERE DISEASE DUE TO TOXOPLASMA-GONDII IN HIV-POSITIVE PATIENTS
    STELLBRINK, HJ
    FUHRERBUROW, R
    RAEDLER, A
    ALBRECHT, H
    FENSKE, S
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1993, 9 (06) : 633 - 637
  • [10] Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders
    Wilde, JT
    Lee, CA
    Collins, P
    Giangrande, PLF
    Winter, M
    Shiach, CR
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (03) : 556 - 559